Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

Recruitment Status
RECRUITING
(See Contacts and Locations)Verified March 2026 by AbbVie
Sponsor
AbbVie
Information Provided by (Responsible Party)
AbbVie
Clinicaltrials.gov Identifier
NCT05407636
Other Study ID Numbers:
RGX-314-3101
First Submitted
January 27, 2022
First Posted
June 6, 2022
Last Update Posted
April 19, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on April 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

This randomized, partially masked, controlled, Phase 3 clinical study will evaluate the efficacy and safety of ABBV-RGX-314 gene therapy in participants with nAMD. The study will evaluate 2 dose levels of RGX-314 gene therapy relative to an active comparator. The primary endpoint of this study is mean change in best-corrected visual acuity (BCVA) of ABBV-RGX-314 relative to aflibercept. Approximately 714 participants who meet the inclusion/exclusion criteria, will be enrolled into one of 3 arms.

A bilateral treatment substudy conducted at US sites is an open-label, partially randomized, parallel arm study to evaluate the safety and efficacy of subretinal ABBV-RGX-314 administered bilaterally in participants who have bilateral nAMD. Previously treated crossover participants from the control arm of the main study who crossed over and received ABBV-RGX-314 in the study eye will receive the same ABBV-RGX-314 dose in the contralateral eye (ie, same dose as in the study eye), while newcomers (participants who have not been randomized in an ABBV-RGX-314 study) and untreated crossover participants (ongoing control participants in the main study who have completed Week 54 but have not crossed over to receive ABBV-RGX-314 in the main study) will be randomized in a 2:1 ratio to receive ABBV-RGX-314 Dose 1 or ABBV-RGX-314 Dose 2 in both eyes. Up to 15 participants who qualify for the substudy will be enrolled and followed for a minimum of 50 weeks.

Condition or DiseaseIntervention/Treatment
AMDnAMDWet Age-related Macular DegenerationwAMDWetAMDCNV
Genetic: ABBV-RGX-314 Dose 1Genetic: ABBV-RGX-314 Dose 2Biological: Aflibercept (EYLEA®)

Study Design

Study TypeInterventional
Actual Enrollment714 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingQuadruple
Primary PurposeTreatment
Official TitleA Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD
Study Start DateJanuary 12, 2022
Actual Primary Completion Date4mos 2w from now
Actual Study Completion Date1yr 5mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
ABBV-RGX-314 Dose 1
ABBV-RGX-314 Dose 1 administered via subretinal delivery one time.
Genetic: ABBV-RGX-314 Dose 1
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)
ABBV-RGX-314 Dose 2
ABBV-RGX-314 Dose 2 administered via subretinal delivery one time.
Genetic: ABBV-RGX-314 Dose 2
AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)
Control Arm
Aflibercept administered via intravitreal injection approximately every 8 weeks
Biological: Aflibercept (EYLEA®)
2.0 mg (0.05 mLsolution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections

Outcome Measures

Primary Outcome Measures
  1. Mean change from baseline in Best Corrected Visual Acuity (BCVA)
    To evaluate the noninferiority of ABBV-RGX-314 relative to aflibercept in mean change from Baseline BCVA at Week 54
  2. Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEs
    AEs and SAEs through Week 50
Secondary Outcome Measures
  1. Incidences of ocular and overall AEs
    To evaluate the safety and tolerability of ABBV-RGX-314 through Week 54
  2. Proportion of participants with improved BCVA
    To evaluate the effect of ABBV-RGX-314 relative to aflibercept on BCVA
  3. Proportion of participants with worsened BCVA
    To evaluate the effect of ABBV-RGX-314 relative to aflibercept on BCVA
  4. Proportion of participants (1) gaining or losing greater than 0 letters; (2) maintaining vision compared with baseline as per BCVA
    To evaluate the effect of ABBV-RGX-314 relative to aflibercept on BCVA
  5. Mean change from baseline in BCVA for participants who received 0 or more supplemental anti-VEGF injection (ABBV-RGX- 314 randomized participants)
    To evaluate the effect of ABBV-RGX-314 relative to aflibercept on BCVA
  6. Mean change from Week 54 to Week 108 in BCVA (control arm participants who cross over to ABBV-RGX-314)
    To evaluate the effect of ABBV-RGX-314 relative to aflibercept on BCVA
  7. Mean change in central retinal thickness (CRT) as measured by SD-OCT
    To evaluate the effect of ABBV-RGX-314 relative to aflibercept on CRT as measured by SD-OCT
  8. Mean change in central point thickness (CPT) as measured by SD-OCT
    To evaluate the effect of ABBV-RGX-314 relative to aflibercept on CPT as measured by SD-OCT
  9. Mean number of supplemental anti-VEGF injections from Baseline through Week 54 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 108 (control arm participants who cross over to ABBV-RGX-314)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  10. Proportion of participants with 0, 1, 2, and 3 supplemental injections through Week 54 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 108 (control arm participants who cross over to ABBV-RGX-314)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  11. Proportion of participants with ≤ 1, ≤ 2, and ≤ 3 supplemental injections through Week 54 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 108 (control arm participants who cross over to ABBV-RGX-314)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  12. Proportion of participants that received 1 or 2 injections through Week 54 (ABBV-RGX-314 randomized participants) and from Week 54 through Week 108 (control arm participants who cross over to ABBV-RGX-314)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  13. Proportion of participants with a reduction of ≥ 50% in anti-VEGF injection annualized rate through Week 54 compared with the prior year (ABBV-RGX-314 randomized participants)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  14. Proportion of participants with a reduction of ≥ 75% in anti-VEGF injection annualized rate through Week 54 compared with the prior year (ABBV-RGX-314 randomized participants)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  15. Percent reduction in anti-VEGF injection annualized rate through Week 54 compared with the prior year (ABBV-RGX-314 randomized participants)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  16. Supplemental anti-VEGF injection annualized rate through Week 54 (ABBV-RGX-314 randomized participants)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  17. Percent reduction in anti-VEGF injection annualized rate after Week 58 through Week 108 relative to the year prior to study (control arm participants who cross over to ABBV-RGX-314)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  18. Supplemental anti-VEGF injection annualized rate after Week 58 through Week 108 (control arm participants who cross over to ABBV-RGX-314)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  19. Time to first supplemental anti- VEGF injection after the Week 2 injection (ABBV-RGX-314 randomized participants)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  20. Time to first supplemental anti-VEGF injection after the Week 58 injection (control arm participants who cross over to ABBV-RGX-314)
    To assess the need for supplemental anti-VEGF therapy in participants treated with ABBV-RGX-314
  21. Mean change from Baseline in NEI VFQ-25 (composite score) at Week 54 and (control arm participants who cross over to ABBV-RGX-314) Week 108
    To evaluate patient-reported visual function and treatment satisfaction using PRO questionnaires
  22. Mean change from Baseline in MacTSQ (composite score) at Week 54 and (control arm participants who cross over to ABBV-RGX-314) Week 108
    To evaluate patient-reported visual function and treatment satisfaction using PRO questionnaires
  23. Aqueous humor ABBV-RGX-314 TP concentrations at Week -2, Week 14, Week 38, and Week 54 (ABBV-RGX-314 randomized participants)
    To assess aqueous humor and serum TP concentrations prior to and after ABBV-RGX-314 administration
  24. Aqueous humor ABBV-RGX-314 TP concentrations at Week 54, Week 74, Week 90, and Week 108 (control arm participants who cross over to ABBV-RGX-314)
    To assess aqueous humor and serum TP concentrations prior to and after ABBV-RGX-314 administration
  25. Serum ABBV-RGX-314 TP concentrations (at select sites)
    To assess aqueous humor and serum TP concentrations prior to and after ABBV-RGX-314 administration
  26. Immunogenicity measurements (ABBV-RGX-314 randomized participants)
    Immunogenicity measurements (serum antibodies to AAV8 and serum antibodies to ABBVRGX- 314 TP)
  27. Immunogenicity measurements (control arm participants who cross over to ABBV-RGX-314)
    Immunogenicity measurements (serum antibodies to AAV8 and serum antibodies to ABBV-RGX- 314 TP)
  28. Bilateral Treatment Substudy: Incidence of nonocular AEs and any AESIs
    To evaluate the safety and tolerability of bilateral treatment of ABBV-RGX-314 gene therapy
  29. Bilateral Treatment Substudy: Mean change from Baseline in BCVA at assessed time points
    BCVA measured by ETDRS
  30. Bilateral Treatment Substudy: Mean change from Baseline in CRT at assessed time points
    Mean change in CRT as measured by SD-OCT
  31. Bilateral Treatment Substudy: Supplemental anti-VEGF injection annualized rate
    Supplemental anti-VEGF injection annualized rate
  32. Bilateral Treatment Substudy: Mean number of supplemental anti-VEGF injections
    Mean supplemental anti-VEGF injections
  33. Bilateral Treatment Substudy: Proportion of participants with 0, ≤ 1, ≤ 2, and ≤ 3 supplemental anti-VEGF injections
    Proportion of participants with 0, ≤ 1, ≤ 2, and ≤ 3 supplemental anti-VEGF injections
  34. Bilateral Treatment Substudy: Aqueous humor and serum ABBV-RGX-314 TP concentrations
    Aqueous humor and serum ABBV-RGX-314 TP concentrations
  35. Bilateral Treatment Substudy: Immunogenicity measurements (serum anti-ABBV-RGX-314 TP antibodies, serum anti-AAV8 antibodies) and enzyme-linked immunospot at assessed time points
    Immunogenicity measurements

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
1. Age ≥ 50 years and ≤ 89 years 2. An ETDRS BCVA letter score between ≤ 78 and ≥ 40 in the study eye 3. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in the study eye previously treated with anti-VEGF 4. Must be pseudophakic (at least 12 weeks postcataract surgery) in the study eye 5. Willing and able to provide written, signed informed consent for this study 6. Participants must have demonstrated a meaningful response to anti-VEGF therapy at study entry Inclusion Criteria (Bilateral Treatment Substudy)\
: 1. An ETDRS BCVA letter score between ≤ 83 and ≥ 40 in both eyes 2. Diagnosis of subfoveal choroidal neovascularization (CNV) secondary to AMD in both eyes 3. Must be pseudophakic (at least 12 weeks postcataract surgery) in both eyes 4. Willing and able to provide written, signed informed consent for this study 5. Newcomers must have active disease in the study eye; crossover participants must have active disease in the eye not treated in the main study
Exclusion Criteria
1. CNV or macular edema in the study eye secondary to any causes other than AMD 2. Subfoveal fibrosis or atrophy in the study eye 3. Any condition in the investigator's opinion that could limit VA improvement in the study eye 4. Advanced glaucoma or history of secondary glaucoma in the study eye 5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months 6. History of intraocular surgery in the study eye within 12 weeks prior to randomization 7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6 8. Prior treatment with gene therapy Exclusion Criteria (Bilateral Treatment Substudy)\
: 1. CNV or macular edema in either eye secondary to any causes other than AMD 2. Subfoveal fibrosis or atrophy in either eye 3. Any condition in the investigator's opinion that could limit VA improvement in either eye 4. Advanced glaucoma or history of secondary glaucoma in either eye 5. Myocardial infarction, cerebrovascular accident, or transient ischemic attack within the past 6 months 6. History of intraocular surgery in either eye within 12 weeks prior to randomization 7. History of intravitreal therapy in the study eye, such as intravitreal steroid injection or investigational medicinal product, other than an intravitreal therapy for AMD, in the 6 months prior to Week -6. 8. Prior treatment with gene therapy (\
) For previously treated crossover participants, criteria apply to the eye not treated in the main study only. Note: Other inclusion/exclusion criteria apply

Contacts and Locations

Sponsors and CollaboratorsAbbVie
Locations
Barnet Dulaney Eye Center-Phoenix /ID# 256340 | Phoenix Arizona, United States, 85016Retinal Research Institute /ID# 256238 | Phoenix Arizona, United States, 85053Retina Macula Institute of Arizona /ID# 271026 | Scottsdale Arizona, United States, 85255-4134California Retina Consultants - Bakersfield /ID# 256240 | Bakersfield California, United States, 93309-1677Retina Vitreous Assoc Med Grp /ID# 256246 | Beverly Hills California, United States, 90211Retinal Diagnostic Center /ID# 256262 | Campbell California, United States, 95008The Retina Partners - Encino /ID# 259660 | Encino California, United States, 91436Retina Consultants of Orange County /ID# 256267 | Fullerton California, United States, 92835Jacobs Retina Center at UCSD/ID# 256320 | La Jolla California, United States, 92093California Retina Consultants - Oxnard - North Ventura Road /ID# 262883 | Oxnard California, United States, 93036Byers Eye Institute Stanford /ID# 262853 | Palo Alto California, United States, 94303Retina Consultants of San Diego /ID# 256258 | Poway California, United States, 92064-2530Kaiser Permanente - Riverside Medical Center /ID# 262413 | Riverside California, United States, 92505UC Davis Health Eye Center | Sacramento California, United States, 95817Retinal Consultants Medical Group, Inc. - Greenback /ID# 256353 | Sacramento California, United States, 95841Orange County Retina Medical Group /ID# 256286 | Santa Ana California, United States, 92705Macula Retina Vitreous Center - Torrance /ID# 270247 | Torrance California, United States, 90503Bay Area Retina Associates - Walnut Creek - Lennon Lane /ID# 268513 | Walnut Creek California, United States, 94598Retina Consultants of Southern Colorado /ID# 256285 | Colorado Springs Colorado, United States, 80909Southwest Retina Research Center /ID# 256261 | Durango Colorado, United States, 81303Colorado Retina Associates /ID# 256378 | Lakewood Colorado, United States, 80228Advanced Vision Research Institute /ID# 256380 | Longmont Colorado, United States, 80503Retina Consultants, P.C. /ID# 273610 | Manchester Connecticut, United States, 06042-3556Rand Eye Institute /ID# 256337 | Deerfield Beach Florida, United States, 33064National Ophthalmic Research Institute /ID# 256344 | Fort Myers Florida, United States, 33912-7125Vitreoretinal Associates, P.A. /ID# 256266 | Gainesville Florida, United States, 32607Florida Retina Consultants /ID# 256321 | Lakeland Florida, United States, 33805Florida Retina Institute - Orlando /ID# 256373 | Orlando Florida, United States, 32806-1101Retina Specialty Institute /ID# 256268 | Pensacola Florida, United States, 32503Fort Lauderdale Eye Institute /ID# 266011 | Plantation Florida, United States, 33324Retina Vitreous Associates of Florida - St. Petersburg /ID# 256279 | St. Petersburg Florida, United States, 33711-1141Center for Retina and Macular Disease /ID# 256335 | Winter Haven Florida, United States, 33880Georgia Retina - Marietta /ID# 256264 | Marietta Georgia, United States, 30060Retina Consultants of Hawaii /ID# 256278 | ‘Aiea Hawaii, United States, 96701Northwestern Memorial Hospital - Department of Ophthalmology /ID# 256379 | Chicago Illinois, United States, 60611-2987University Retina and Macula Associates /ID# 256288 | Lemont Illinois, United States, 60439University Retina and Macula Associates /ID# 256287 | Oak Forest Illinois, United States, 60452Illinois Retina Associates - Oak Park /ID# 256375 | Oak Park Illinois, United States, 60304Springfield Clinic - First /ID# 256371 | Springfield Illinois, United States, 62702Retina Partners Midwest, PC /ID# 256277 | Indianapolis Indiana, United States, 46290John-Kenyon American Eye Institute -New Albany /ID# 256283 | New Albany Indiana, United States, 47150Wolfe Eye Clinic - West Des Moines /ID# 256314 | West Des Moines Iowa, United States, 50266Retina Associates - Lenexa /ID# 258296 | Lenexa Kansas, United States, 66215Maine Eye Center - Marginal Way Campus /ID# 256391 | Portland Maine, United States, 04101Retina Specialists /ID# 256392 | Baltimore Maryland, United States, 21204Johns Hopkins Hospital /ID# 256236 | Baltimore Maryland, United States, 21287Mid Atlantic Retina Specialists - Hagerstown /ID# 256310 | Hagerstown Maryland, United States, 21740-5965MA Eye & Ear Infirmary /ID# 262430 | Boston Massachusetts, United States, 02114Ophthalmic Consultants of Boston /ID# 256233 | Boston Massachusetts, United States, 02114Vitreo Retinal Associates - Worcester /ID# 266008 | Worcester Massachusetts, United States, 01605Retina Associates of Michigan /ID# 256393 | Grand Blanc Michigan, United States, 48439Associated Retinal Consultants /ID# 256269 | Royal Oak Michigan, United States, 48073VitreoRetinal Surgery PLLC DBA Retina Consultants of Minnesota /ID# 256272 | Edina Minnesota, United States, 55435Mayo Clinic - Rochester /ID# 258295 | Rochester Minnesota, United States, 55905-0001Mississippi Retina Associates /ID# 270934 | Madison Mississippi, United States, 39110-2028Mid America Surgery Center /ID# 258993 | Chesterfield Missouri, United States, 63017University of Missouri Hospital /ID# 262474 | Columbia Missouri, United States, 65212Washington University School of Medicine - St. Louis /ID# 256383 | St Louis Missouri, United States, 63108Sierra Eye Associates /ID# 256239 | Reno Nevada, United States, 89502Envision Ocular, LLC /ID# 256367 | Bloomfield New Jersey, United States, 07003Monmouth Retina Consultants /ID# 275895 | Little Silver New Jersey, United States, 07739Columbia University of New York - Edward S. Harkness Eye Institute /ID# 256342 | New York New York, United States, 10032Retina Associates of Western New York /ID# 256374 | Rochester New York, United States, 14620Asheville Eye Associates- Retina Division /ID# 256355 | Asheville North Carolina, United States, 28803Duke University Medical Center /ID# 256245 | Durham North Carolina, United States, 27710Graystone Eye /ID# 256424 | Hickory North Carolina, United States, 28602Cincinnati Eye Institute /ID# 256247 | Cincinnati Ohio, United States, 45242-5664Retina Associates of Cleveland-Middleburg Heights /ID# 256280 | Cleveland Ohio, United States, 44130Cleveland Clinic - Cleveland /ID# 256282 | Cleveland Ohio, United States, 44195Ohio State University /ID# 256275 | Columbus Ohio, United States, 43210Midwest Retina /ID# 276644 | Dublin Ohio, United States, 43016Retina Vitreous Center, Research /ID# 256284 | Edmond Oklahoma, United States, 73013University of Pennsylvania /ID# 258995 | Philadelphia Pennsylvania, United States, 19104-5502Mid Atlantic Retina /ID# 256232 | Philadelphia Pennsylvania, United States, 19107University of Pittsburgh Medical Center /ID# 258994 | Pittsburgh Pennsylvania, United States, 15213Charleston Neuroscience Institute - Beaufort /ID# 256385 | Beaufort South Carolina, United States, 29902-6216Charleston Neurosciences Institute /ID# 256351 | Charleston South Carolina, United States, 29414-5896Palmetto Retina Center-Florence /ID# 256244 | Florence South Carolina, United States, 29501Charleston Neurosciences Institute /ID# 256336 | Ladson South Carolina, United States, 29414-5896Black Hills Regional Eye Institute /ID# 262872 | Rapid City South Dakota, United States, 57701Southeastern Retina Associates - Chattanooga /ID# 258992 | Chattanooga Tennessee, United States, 37421Charles Retina Institute /ID# 256237 | Germantown Tennessee, United States, 38138Southeastern Retina Associates - Johnson City /ID# 256396 | Johnson City Tennessee, United States, 37604Tennessee Retina - Nashville /ID# 256388 | Nashville Tennessee, United States, 37203-1513Vanderbilt University Medical Center /ID# 256372 | Nashville Tennessee, United States, 37232-0011Retina Research Institute of Texas /ID# 256263 | Abilene Texas, United States, 79606-1224Austin Research Center for Retina /ID# 256265 | Austin Texas, United States, 78705Austin Clinical Research, LLC /ID# 256274 | Austin Texas, United States, 78750-2298Retina Consultants of Texas - Bellaire /ID# 256377 | Bellaire Texas, United States, 77401Star Retina - Burleson /ID# 256376 | Burleson Texas, United States, 76028Texas Retina Associates /ID# 256259 | Dallas Texas, United States, 75231Texas Retina Associates - Fort Worth /ID# 256326 | Fort Worth Texas, United States, 76104Austin Retina Associates - Round Rock /ID# 256387 | Round Rock Texas, United States, 78681Retina Consultants of Texas/ID# 259661 | San Antonio Texas, United States, 78240-1655Retina Associates of South Texas | San Antonio Texas, United States, 78240Retina Consultants of Texas /ID# 256382 | San Antonio Texas, United States, 78251Retina Center Of Texas (Rct) - Southlake /ID# 256281 | Southlake Texas, United States, 76092Rocky Mountain Retina Consultants /ID# 256369 | Murray Utah, United States, 84107Retina Associates of Utah /ID# 256276 | Salt Lake City Utah, United States, 84107Piedmont Eye Center /ID# 256386 | Lynchburg Virginia, United States, 24502Wagner Kapoor Research Institute - Norfolk /ID# 256260 | Norfolk Virginia, United States, 23502Retina Institute of Virginia /ID# 256394 | Richmond Virginia, United States, 23235Vistar Eye Center /ID# 271024 | Roanoke Virginia, United States, 24019Pacific Northwest Retina /ID# 258999 | Bellevue Washington, United States, 98004Retina Center NW, PLLC /ID# 256395 | Silverdale Washington, United States, 98383Spokane Eye Clinic /ID# 256338 | Spokane Washington, United States, 99204Gundersen Health System - La Crosse Medical Center /ID# 276012 | La Crosse Wisconsin, United States, 54601Calgary Retina Consultants /ID# 258997 | Calgary Alberta, Canada, T2H 0C8Alberta Retina Consultants /ID# 265599 | Edmonton Alberta, Canada, T5H 0X5Retina Surgical Associates /ID# 270958 | New Westminster British Columbia, Canada, V3L 5H1University of British Columbia - Eye Care Centre, Vancouver General Hospital /ID# 266014 | Vancouver British Columbia, Canada, V5Z 3N9Vitreous Retina Macula Specialists of Toronto /ID# 258299 | Etobicoke Ontario, Canada, M8X 2X3Ottawa Hospital Research Institute /ID# 258998 | Ottawa Ontario, Canada, K1H 8L6Retina Centre of Ottawa /ID# 259659 | Ottawa Ontario, Canada, K2B 7E9Toronto Retina Institute /ID# 265602 | Toronto Ontario, Canada, M3C 0G9Sunnybrook Research Institute /ID# 270690 | Toronto Ontario, Canada, M4N 3M5CHU de Quebec-Universite Laval /ID# 258996 | Québec Quebec, Canada, G1R 2J6Centre Hospitalier Universitaire de Nice - Hopital Pasteur /ID# 262418 | Nice Alpes-Maritimes, France, 06001Hôpital de la Croix Rousse - Groupement Hospitalier Nord /ID# 262409 | Lyon Auvergne-Rhône-Alpes, France, 69004CHU Dijon /ID# 262410 | Dijon Cote-d Or, France, 21000Chu De Toulouse - Hopital Pierre Paul Ricquet /ID# 262411 | Toulouse Occitanie, France, 31059Hopitaux Universitaires Paris Centre-Hopital Cochin /ID# 262415 | Paris Paris, France, 75679Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 262408 | Nantes Pays de la Loire Region, France, 44000Clinique Juge /ID# 262417 | Marseille Provence-Alpes-Côte d'Azur Region, France, 13008Centre Hosp Intercommunal de Creteil /ID# 262407 | Créteil Val-de-Marne, France, 94000Clinique Honoré Cave /ID# 262225 | Montauban , France, 82017AP-HP - Groupe Hospitalier 10e - Hopital Lariboisiere /ID# 262406 | Paris , France, 75010Universitaetsklinikum Freiburg /ID# 262495 | Freiburg im Breisgau Baden-Wurttemberg, Germany, 79106Universitaetsklinikum Ulm /ID# 262494 | Ulm Baden-Wurttemberg, Germany, 89081Universitaetsklinikum Bonn /ID# 262498 | Bonn North Rhine-Westphalia, Germany, 53127Universitaetsklinikum Muenster /ID# 262499 | Münster North Rhine-Westphalia, Germany, 48149Klinikum Ludwigshafen /ID# 262497 | Ludwigshafen am Rhein Rhineland-Palatinate, Germany, 67063Universitaetsklinikum Hamburg-Eppendorf /ID# 262493 | Hamburg , Germany, 20246Knappschaftsklinikum Saar /ID# 262496 | Püttlingen , Germany, 66346Debreceni Egyetem-Klinikai Kozpont /ID# 262646 | Debrecen Hajdú-Bihar, Hungary, 4032Budapest Retina Intezet /ID# 262647 | Budapest , Hungary, 1133Ganglion Orvosi Központ /ID# 264550 | Pécs , Hungary, 7621Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale S.Anna /ID# 262896 | Cona Ferrara, Italy, 44124IRCCS Ospedale San Raffaele /ID# 263035 | Milan Milano, Italy, 20132ASST Fatebenefratelli Sacco /ID# 263273 | Milan Milano, Italy, 20157Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 264074 | Naples Napoli, Italy, 80138Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 263037 | Rome Roma, Italy, 00168IRCCS Fondazione G.B. Bietti per lo studio e la ricerca in Oftalmologia- ONLUS /ID# 262897 | Rome Roma, Italy, 00184IRCCS Ospedale Sacro Cuore Don Calabria /ID# 263536 | Negrar Verona, Italy, 37024A.O.U. Consorziale Policlinico di Bari /ID# 262500 | Bari , Italy, 70124ASL 2 Abruzzo Lanciano-Vasto-Chieti /ID# 263923 | Chieti , Italy, 67100ASU FC - P.O. Universitario Santa Maria della Misericordia /ID# 263036 | Udine , Italy, 33100Nagoya University Hospital /ID# 267350 | Nagoya Aichi-ken, Japan, 466-8560Fukushima Medical University Hospital /ID# 258411 | Fukushima Fukushima, Japan, 960-1295Kobe City Eye Hospital /ID# 256948 | Kobe Hyōgo, Japan, 650-0047Hyogo Medical University Hospital /ID# 257893 | Nishinomiya-shi Hyōgo, Japan, 663-8501Kagoshima University Hospital /ID# 257053 | Kagoshima Kagoshima-ken, Japan, 890-8520Kyoto University Hospital /ID# 267351 | Kyoto Kyoto, Japan, 606-8507University of Miyazaki Hospital /ID# 262879 | Miyazaki Miyazaki, Japan, 889-1692Shiga University of Medical Science /ID# 266862 | Ōtsu Shiga, Japan, 520-2192Juntendo University Hospital /ID# 258715 | Bunkyo-ku Tokyo, Japan, 113-8431Emanuelli Research & Development Center LLC /ID# 256231 | Arecibo , Puerto Rico, 00612Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 262632 | Santiago de Compostela A Coruna, Spain, 15706Hospital Universitari de Bellvitge /ID# 262641 | L'Hospitalet de Llobregat Barcelona, Spain, 08907Hospital Arruzafa /ID# 262634 | Córdoba Cordoba, Spain, 14012Complejo Hospitalario Universitario Insular-Materno Infantil de Gran Canaria /ID# 262633 | Las Palmas de Gran Canaria Las Palmas, Spain, 35016Hospital Universitario Puerta de Hierro - Majadahonda /ID# 262635 | Majadahonda Madrid, Spain, 28222Institut Clínic d'Oftalmologia (ICOF). Hospital Clínic d'Oftalmologia. /ID# 262644 | Barcelona , Spain, 08028Instituto de Microcirugía Ocular /ID# 262642 | Barcelona , Spain, 08035Hospital Santa Creu i Sant Pau /ID# 262637 | Barcelona , Spain, 08041Hospital Universitario 12 de Octubre /ID# 262636 | Madrid , Spain, 28041Clinica Baviera /ID# 270146 | Madrid , Spain, 28046Stoke Mandeville Hospital /ID# 277343 | Aylesbury Buckinghamshire, United Kingdom, HP21 8ALWestern Eye Hospital /ID# 271621 | London England, United Kingdom, NW1 5QHGloucestershire Royal Hospital /ID# 277362 | Gloucester Gloucestershire, United Kingdom, GL1 3NNMoorfields Eye Hospital /ID# 263038 | London Greater London, United Kingdom, EC1V 2PDThe Retina Clinic London /ID# 262304 | London Greater London, United Kingdom, W1G 7LBUniversity Hospital Southampton NHS Foundation Trust /ID# 262307 | Southampton Hampshire, United Kingdom, SO16 6YDOxford University Hospitals NHS Foundation Trust /ID# 262306 | Oxford Oxfordshire, United Kingdom, OX3 9DULeeds Teaching Hospital /ID# 277366 | Leeds West Yorkshire, United Kingdom, LS9 7TFBradford Royal Infirmary /ID# 273164 | Bradford , United Kingdom, BD9 6RJBristol Eye Hospital /ID# 271619 | Bristol , United Kingdom, BS1 2LXLiverpool University Hospitals NHS Foundation Trust /ID# 262305 | Liverpool , United Kingdom, L7 8XPManchester University NHS Foundation Trust /ID# 262404 | Manchester , United Kingdom, M9 2AARoyal Victoria Infirmary /ID# 277368 | Newcastle upon Tyne , United Kingdom, NE1 4LPSunderland Eye Infirmary /ID# 271620 | Sunderland , United Kingdom, SR2 9HP